China’s regulators have just released the finalized list of foreign novel drugs that are slated for priority reviews due to urgent clinical need. Out of the 48 listed products, eight have already been approved recently and the remaining 40 should see new drug application (NDA) filings soon, noted the National Medical Products Administration (NMPA).
Upon the submissions, the administration’s Center for Drug Evaluation (CDE) will set up a special process to speed up reviews of these new drugs, and planned market authorization holders will be able to apply to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?